Walleye Capital’s Structure Therapeutics GPCR Stock Holding History

Walleye Capital’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$366K	Sell	7,600 -300	-4%	-$20.5K	﹤0.01%	2905
2025 Q4	$549K	Sell	7,900 -300	-4%	-$12.2K	﹤0.01%	2902
2025 Q3	$230K	Buy	8,200 +6,800	+486%	+$135K	﹤0.01%	3228
2025 Q2	$29K	Buy	+1,400	New	+$30.8K	﹤0.01%	4178
2025 Q1	–	Sell	-600	Closed	-$16.3K	–	4574
2024 Q4	$16.3K	Buy	+600	New	+$21.3K	﹤0.01%	4530
2024 Q3	–	Sell	-1,600	Closed	-$62.8K	–	5496
2024 Q2	$62.8K	Sell	1,600 -300	-16%	-$12.3K	﹤0.01%	4870
2024 Q1	$81.4K	Buy	+1,900	New	+$80.1K	﹤0.01%	4494

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Walleye Capital's GPCR Position: Q1 2026 in Review

Walleye Capital increased its Structure Therapeutics (GPCR) stake by 1,067,900% in Q1 2026, buying an estimated $1.46M and bringing the position to 21,360 shares worth $1.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2049.

Walleye Capital first reported a position in GPCR in Q1 2024 and has held it in 7 quarters since. The position peaked at $4.02M in Q1 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Walleye Capital held 21,360 shares of Structure Therapeutics worth $1.03M as of Q1 2026.
Walleye Capital bought 21,358 Structure Therapeutics shares in Q1 2026, an estimated $1.46M.
Structure Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2049 holding.
Walleye Capital first reported a position in Structure Therapeutics in Q1 2024 and has held it in 7 quarters since.
Walleye Capital's Structure Therapeutics position peaked at $4.02M in Q1 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.